Sonoma Pharmaceuticals Inc (NASDAQ: SNOA) is a specialty pharmaceutical company that develops and commercializes hypochlorous acid (HOCl)-based products for dermatological and advanced tissue care applications. Revenue comes from direct product sales and from licensing and distribution agreements with regional partners across more than 55 countries. The company sells both prescription and over-the-counter products under brands including Microcyn, Levicyn, Celacyn, Lasercyn, Epicyn, Acuicyn, Ocucyn, and others, targeting wound care, scar management, eczema, acne, and eye hygiene indications. A substantial portion of revenues derives from international markets, primarily Mexico and Europe, where the company operates subsidiaries. Customer concentration is material: as of March 31, 2025, a single customer (customer D) represented 24% of net accounts receivable. The company was originally incorporated in 1999 as Micromed Laboratories, Inc., rebranded as Oculus Innovative Sciences in 2001, and adopted the Sonoma Pharmaceuticals name. It has never paid a cash dividend.

Revenue model

Transactional product sales of HOCl-based prescription and OTC products, supplemented by exclusive license and distribution agreements with regional partners such as Dyamed Biotech Pte Ltd. and Anlicare International for international markets.

Products and services

HOCl-based topical products across wound care, dermatology, scar management, and eye hygiene: Microcyn Wound Care Management, Levicyn Antimicrobial Dermal Spray and Gel, Celacyn Scar Management Gel, Lasercyn Post Procedure Gel and Dermal Spray, Epicyn Antimicrobial Facial Cleanser, Acuicyn Antimicrobial Eyelid & Eyelash Hygiene, Ocucyn Eyelid & Eyelash Cleanser, Regenacyn Plus and Advanced Scar Gel, Rejuvacyn Plus and Advanced Skin Repair Cooling Mist, Reliefacyn Plus and Advanced Itch-Burn-Rash-Pain Relief Hydrogel, Lumacyn Clarifying Mist, Podiacyn Advanced Everyday Foot Care. Prescription and office-dispense dermatology products were relaunched for direct U.S. sale in December 2024.

Customers and end markets

Physicians, dermatologists, other medical staff, and patients in wound care, dermatology, and eye hygiene end markets. Customer concentration is material: customer D represented 24% of net accounts receivable as of March 31, 2025. Products are sold in the U.S. and internationally through distribution partners across more than 55 countries.

Value-chain role

Product developer and manufacturer of HOCl-based topical therapeutics, selling direct in the U.S. and through exclusive regional licensing and distribution partners internationally. Holds regulatory approvals including FDA clearances and an updated CE certificate under the EU Medical Devices Regulation received January 29, 2025.

Geographic exposure

United States, Mexico (functional currency: Mexican Peso), and Europe including the Netherlands (functional currency: Euro). International sales, primarily from Mexico and Europe, represent a substantial portion of total revenues per the FY2025 10-K filed June 17, 2025. Products ship into more than 55 countries.

Source: SEC 10-K, filed 2025-06-17

Industry: Surgical & Medical Instruments & Apparatus Peers: Enveric Biosciences Inc CANBIOLA, INC. Evoke Pharma Inc Kiora Pharmaceuticals Inc Grapefruit USA, Inc GREEN HYGIENICS HOLDINGS INC. Johnson & Johnson One World Products Inc Stablecoin Development Corp Stem Holdings, Inc.